Although ras and p53 are the most commonly found oncogene and tumor suppressor gene, respectively, in human cancers, their collective roles in tumor progression have yet to be defined in animal models. Here, we demonstrated the synergistic effect between ras and p53 in promoting tumor progression during lung tumorigenesis using bitransgenic mice. Mice with a heterozygous knockout of K-ras (K-ras wt/ko ) were mated to p53 transgenic mice (p53 ). F 1 mice exhibited a significant increase in lung tumor load (tumor multiplicity Â tumor volume) when compared to those seen in either K-ras wt/ko mice or p53 val135/wt mice alone. Furthermore, over 50% of the lung tumors were lung adenocarcinomas in bitransgenic mice compared to only 3% in wild-type mice. Alterations of ras and p53 appear to promote the development of lung adenocarcinomas. These results provide the in vivo experimental evidence of synergistic interactions of ras and p53 in lung tumor progression.
Although ras and p53 are the most commonly found oncogene and tumor suppressor gene, respectively, in human cancers, their collective roles in tumor progression have yet to be defined in animal models. Here, we demonstrated the synergistic effect between ras and p53 in promoting tumor progression during lung tumorigenesis using bitransgenic mice. Mice with a heterozygous knockout of K-ras (K-ras wt/ko ) were mated to p53 transgenic mice (p53 val135/wt ) in lung tumorigenesis (K-ras wt/ko Â p53 val135/wt ). F 1 mice exhibited a significant increase in lung tumor load (tumor multiplicity Â tumor volume) when compared to those seen in either K-ras wt/ko mice or p53 val135/wt mice alone. Furthermore, over 50% of the lung tumors were lung adenocarcinomas in bitransgenic mice compared to only 3% in wild-type mice. Alterations of ras and p53 appear to promote the development of lung adenocarcinomas. These results provide the in vivo experimental evidence of synergistic interactions of ras and p53 in lung tumor progression. Keywords: lung; cancer; progression; ras; p53; transgenic mice Activated ras genes have been detected in spontaneously occurring and chemically induced tumors generated in numerous experimental rodent models (Guerrero and Pellicer, 1987; Balmain and Brown, 1988; Herzog et al., 1997) . For example, K-ras oncogenes are frequently detected in mouse lung tumors (You et al., 1989; Devereux et al., 1991; Chen et al., 1994a, b; Herzog et al., 1997) . Activating point mutations in the K-ras gene have been detected in 30-50% of human lung adenocarcinomas (Slebos and Rodenhuis, 1992; Husgafvel-Pursiainen et al., 1993; Westra et al., 1993a, b; Vachtenheim, 1997) and in B80% of spontaneously occurring and chemically induced mouse lung tumors (Candrian et al., 1991; You et al., 1991 You et al., , 1993 Wang et al., 1993; Chen et al., 1993 Chen et al., , 1994a Matzinger et al., 1995) . Heterozygous K-ras-deficient mice have an increased susceptibility to the chemical induction of lung tumors when compared with wild-type (wt) mice, suggesting that loss of the wt K-ras allele promotes activating K-ras mutation-driven lung carcinogenesis (Zhang et al., 2001) . The oncogenic alleles of the ras genes have been referred to as dominant oncogenes, as their transforming ability exists when normal ras alleles are also expressed (Barbacid, 1987; Marshall, 1991) .
We reported that a significant increase in lung tumor multiplicity in p53 transgenic mice carrying a dominantnegative mutation . Transgenic mice containing an Ala-to-Val mutation at codon 135 of the p53 gene developed a high incidence of spontaneous tumors, including lung adenocarcinoma (Lavigueur et al., 1989) . Previously, we observed that p53 val135/wt mice exhibit increased susceptibility to the chemical induction of lung cancer by various carcinogens . Introduction of a p53 transgene expressing the mutant p53 protein (Val135) inactivates endogenous wt p53 (Harvey et al., 1995) . We also found that p53 transgenic mice with the germline mutation Ala135Val were more susceptible than wt mice to uterine sarcomas, colon carcinomas and esophageal adenocarcinomas following treatment with chemical carcinogens (Lubet et al., 2000 (Lubet et al., , 2005 Zhang et al., 2000 Zhang et al., , 2002 Zhang et al., , 2003 Wang et al., 2003) .
The availability of mouse models with heterozygous knockout of K-ras and with mutant p53 enables us to address the relationship between ras alteration and p53 mutation in lung carcinogenesis in vivo. In this study, we report the synergistic induction of lung adenocarcinomas in transgenic mice with mutations in ras and p53. In the process, we developed a new mouse model for malignant progression of lung cancer.
As illustrated in Figure 1A , p53 val135/wt mice were crossed with K-ras ko/wt knockout mice to assess the roles of p53 and ras in lung tumor progression. The term 'tumor progression' here is used to describe the process of tumor development from lung adenomas to lung adenocarcinomas, which is closely associated with the increase in the total tumor load (tumor multiplicity Â tumor volume) per mouse. A significant increase was observed in the tumor load in the transgenic mice (K-ras val135/wt and K-ras ko/wt p53 val135/wt ) were divided into four groups and were given single intraperitoneal injection of 60 mg/kg body weight of vinyl carbamate (VC) at B7 weeks of age. VC was purchased from Toronto Research Chemicals Inc. (Toronto, Canada) and was prepared immediately before use. The experiment was ended 7 months after VC treatment ( Figure 1A ). Mice were terminated by CO 2 asphyxiation. Portions of tumor and normal tissue were frozen at À801C. The remaining lung was fixed in Tellyesniczky's solution (90% ethanol (70% (v/v)), 5% glacial acetic acid, 5% formalin (10% (v/v) buffered formalin) overnight, followed by storage in 70% ethanol. After being embedded in paraffin, tissue sections (4 mm) were stained with hematoxylin and eosin for histopathological evaluation. Lung tumor number (N), volume (V) and total tumor load (N Â V per mouse) were evaluated. Student's t-test was used to determine the difference in the tumor load of tumors of lung per mouse between transgenic mice and wt mice. Figure 1C . Lung adenocarcinomas are composed of cells with varying degrees of differentiation, with most cells appearing relatively undifferentiated relative to lung adenomas. There is a complete loss of normal alveolar architecture, and the nuclear: cytoplasmic ratio is increased in the carcinomas. Nuclear crowding and cytologic atypia are present, and there is heterogeneity of growth patterns. Invasion into adjacent bronchioles or vessels is also observed. These results demonstrate that a combination of mutant p53 and K-ras heterozygous deficiency is more effective in enhancing mouse lung tumor progression from lung adenomas to lung adenocarcinomas than the mutant p53 or K-ras heterozygous deficiency alone.
Our observation that mice with a heterozygous deletion of K-ras exhibited increases in VC-induced lung tumor multiplicity, lung tumor load and the number of lung adenocarcinomas when compared to their wt littermates is in agreement with our prior data showing that most of the effects of K-ras heterozygous deficiency are on tumor progression and further support the notion of wt K-ras as a tumor suppressor for the activated ras allele (Zhang et al., 2001) . Thus, ras is both an oncogene and a tumor suppressor as there is increasing evidence that activated ras does not have a dominant role in cell transformation and that wt ras has tumor suppressor activity (Finney and Bishop, 1993; Zhang et al., 2001; Diaz et al., 2002; Thompson et al., 2002; James et al., 2003) . Both hemizygous K-ras and homozygous N-ras knockout mice are highly susceptible to chemically induced lung carcinomas and thymic lymphomas (Zhang et al., 2001; Diaz et al., 2002) . By contrast, mice overexpressing wt N-ras have been shown to be resistant to thymic lymphomagenesis and rats overexpressing K-ras and H-ras are resistant to mammary tumorigenesis (Diaz et al., 2002; Thompson et al., 2002) . Teratomas derived from K-rasÀ/À embryonic stem (ES) cells were significantly larger, contained significantly higher proportions of undifferentiated embryonal carcinoma-like cells and exhibited significantly increased mitotic activity when compared with teratomas derived from wt ES cells (James et al., 2003) . K-ras, therefore, seems to exhibit tumor suppressor activity in the absence of its oncogenic allele and mutations in other genes (James et al., 2003) . Wt ras can reduce proliferation of tumor cells that lack ras mutations, indicating that wt ras is a general inhibitor of the transformed phenotype (Diaz et al., 2002; James et al., 2003) . Interestingly, K-rasÀ/À ES cells also exhibit a greater capacity for stem cell self-renewal in vitro, compared with wt ES cells, and re-expression of wt K-ras in the K-rasÀ/À ES cells reduced this to the levels seen in the wt cells, thus restoring the wt phenotype (James et al., 2003) . There is evidence to suggest that the ability of wt ras to inhibit tumor phenotype might depend upon the type of tissue in which it is expressed (Diaz et al., 2004) . N-ras-deficiency promotes lymphomagenesis in the thymus, whereas it inhibits tumor development in fibroblasts treated with 3-methylcholanthrene and B cells treated with N-nitrosomethylurea (Diaz et al., 2004) . These paradoxical observations indicate that further studies are needed to clarify the function(s) of wt ras in tumorigenesis.
We also found that mice with this p53 mutation exhibited a significant increase in both lung tumor multiplicity and, particularly, lung tumor load as compared to their wt littermates. Our data are consistent with the results of a previous study (Kemp et al., 1993) that showed an increased rate of malignant progression in both p53 heterozygous and p53 homozygous knockout mice. The finding that p53 val135/wt mice are highly susceptible to the chemical induction of mouse lung tumors clearly demonstrates the important role of p53 in lung tumorigenesis. Clinically, patients with a p53 germline mutation (Li-Fraumeni syndrome or LFS) develop lung cancer at a remarkably high rate, even higher in those who are smokers (Hwang et al., 2003) . Lung cancer was found to be the most frequently observed cancer type in adult male p53 mutation carriers in humans with a 50% risk of developing lung cancer by age 60 (Hwang et al., 2003) . Whereas o10% of smokers develop lung cancer, almost 50% of males with LFS develop lung cancer (Hwang et al., 2003) . If individuals with LFS have the average incidence of smokers, this implies a remarkably high penetrance (>80%). This agrees with our results with p53 transgenic mice, which indicated the contribution of p53 mutations to the initial stages of the carcinogenic process. Furthermore, there is a fourfold increase in lung cancer incidence among carriers with p53 mutations who are smokers as compared with those who are nonsmokers (Hwang et al., 2003) , which suggests a profound interaction between tobacco smoke and p53 mutations. This result would seem to parallel our finding of increased susceptibility to the carcinogens.
Since both ras and p53 pathways were disrupted and led to a synergistic effect in chemical induction of lung carcinogenesis, we can conclude that at least two oncogenic changes are required for rapid lung tumor progression. Our findings are consistent with some of the previously published studies. For example, our finding is consistent with the results from Halevy et al. (1990) , in which the mutant p53 gene was found to act synergistically with the mutant ras gene to cause malignant transformation of primary rat embryo cells. Pierceall et al. (1991) reported that inactivation of the p53 tumor suppressor gene, as well as activation of ras oncogenes, may be involved in the pathogenesis of some human skin SCCs. Finally, Fisher et al. (2001) reported that in the absence of p53 gene, doxycyclinemediated induction of K-ras4b G12D initiated lung tumorigenesis much more rapidly than in a wt background. Our data present the in vivo evidence that concurrent expression of a dominant-negative p53 with a heterozygous deficient K-ras can accelerate lung tumor progression. These findings clearly established a role for p53 and ras as the most common and, perhaps, the most important cancer genes in cancer development and progression.
